NCT00984464 - Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 28, 2014

Study Completion Date

October 31, 2014

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL

REOLYSIN

3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle

DRUG

Carboplatin

6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle

DRUG

Paclitaxel

200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle

Trial Locations (1)

Cancer Therapy & Research Center at UTHSCSA, San Antonio